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studies, including and in addition to the EQ-5D, are extracted and added to the data-
base record to create a searchable index of instruments. A beta version of the data-
base, using bespoke software to improve functionality, is currently undergoing ad hoc 
testing. Results: The alpha version of the database contains over 3,500 potentially 
relevant studies identified by the search process. Several hundred studies have been 
data extracted and indexed. The names of over 50 instruments, including quality of 
life, disease specific and generic preference-based measures have been added to the 
index. A programme of sifting, data extraction and indexing is ongoing. Public access 
to the beta version of the database is planned for Autumn 2013. ConClusions: 
The purpose of the health utilities database is to improve access to HSUV evidence, 
in the first instance in studies using the EQ-5D with a view to including all major 
preference-based utility measures.
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objeCtives: To analyze the publications on methodology and normative regu-
lations of pharmacoeconomic studies, including materials providing results of 
conducted researches in Russia or translated international publications, as well 
as to analysis the dynamics of publications and identify the structure of meth-
odological approaches in Russia. Methods: The screening of publications from 
the data of the Central Medical Scientific Library of the First MSMU was conducted 
based on the key words - “pharmacoeconomic*” and “pharmacoeconomical*” with 
corresponding endings. The time horizon of the study was 6 years (from 2007-
2012). Results: By the beginning of 2013, 280 literature sources were found and 
analyzed in the timeline from 2007 to 2013. It was found that the most common 
type of publications for the reporting period have been the inaugural dissertations 
showing the researches results - they are accounted for about 47% of all studies, 
followed by further research reports, accounted for 44%, methodical publications 
- 5%, dissertations devoted to the methodology of the pharmacoeconomics- 3%, 
regulatory guidance documents and translations of foreign studies - 1%. The most 
common structure of published researches was monocenter (56%), with a retro-
spective time-restricted directivity (74%). Russian authors use the methodology of 
the “cost-effectiveness” analyzing in their works the most frequently (48%). 64% of 
Russian researchers take into account only direct costs, 32% of researchers analyze 
their studies based on indirect costs. ConClusions: Based on our review of the 
published works from 2007 to 2012, we can make a conclusion on the formation 
and development of high-grade pharmacoeconomics as an independent research 
area in the Russian Federation.
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objeCtives: Use of proton instead of photon radiation therapy for head and neck 
cancer reduces the primary tumor and damage to adjacent organs risk, which 
results in fewer complications. These complications decrease quality of life (QOL). To 
support better decision making concerning which patients benefit most from pro-
ton therapy, a patient-level simulation model is developed and applied to compare 
outcomes. Methods: Model estimates, such as patient and tumor characteristics, 
follow-up time, and survival, were based on patient-level data containing patients 
treated with radiation therapy as first line therapy for head and neck tumor in The 
Netherlands between 1980–2010 at the UMC Groningen (n= 277) and VU Amsterdam 
(n= 736). In silico radiation treatment planning schemes for both proton and photon 
therapy allowed to compare a priori expected health benefits and cost consequences 
for both therapy modes to support a patient tailored choice. Results: Patients 
experienced their first event at a median time of 30 (0-270, SD 34) months’ time. 
Loco-regional recurrency in 29%, distant metastasis in 4.2%, both combined in 1% 
and dead in 13.3% of patients. Cost per year for photon was estimated € 15000, proton 
€ 30000, disease free state € 190, local regional recurrence € 28000, metastases € 35000, 
and both € 35000. For the complication sticky saliva costs per year of an average 
patient were € 31, xerostomia € 194, dysphagia € 57, tube feeding € 4262, and hypothy-
roidism € 117. Proton radiation therapy leads to less complications and improved 
QOL. ConClusions: Given the high costs of proton therapy, this was found not 
to be cost-effective compared to best photon therapy in an average patient with 
head and neck cancer. However, the outcomes vary substantially between patients. 
Depending on patient and tumor characteristics for selected patients with high 
complication risks, proton therapy can be a better option.
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objeCtives: To assess the overall impact of the production and distribution of 
pharmaceutical products in the Greek economy, in terms of Value Added, GDP, 
employment and tax revenues. Methods: The overall impact in the Greek econ-
omy is estimated as an exogenous change in the economic activity by using the 
Leontief input-output model. Results: The results indicate that the direct effect 
of the industry on domestic economic activity is € 1.5 billion in terms of GDP. The 
indirect effect, which represents the value created by auxiliary sectors as (main 
suppliers) of the pharma industry is € 2.2 billion. Finally, the induced effect, which 
is the impact from the final consumption, as a result of the wages and salaries 
gained by employees across the production chain of the specific industry is € 3.8 
billion. Hence, the overall effect on GDP is approximately € 7.5 billion, which repre-
and nearly half originated from north America (31/69). Emerging themes suggest 
that better accuracy is achieved when patients are answering questions about inpa-
tient and specialist care. ConClusions: There is only a limited amount of valid-
ity and reliability information available to inform best practice for resource-use 
measurement in clinical trials. This ongoing review will identify the gaps, giving a 
clearer view of where research efforts should be concentrated.
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objeCtives: Nowadays, there is a general agreement about the need of includ-
ing future related medical costs in life years gained while no consensus has been 
achieved about future unrelated medical costs (indirect medical costs) and future 
non-medical costs. The aim of this study has been to assess the extension of 
published economic evaluations that incorporated future costs and what types 
of future cost were included. Methods: Three general health economic journals 
(Pharmacoeconomics, Value in Health and European Journal of Health Economics) were 
reviewed to identify economic evaluations from 2008 to 2011. Only complete eco-
nomic evaluations were accepted for this research. From each selected article, future 
cost inclusion was evaluated along with the type of future costs included. Results: 
A total of 148 articles were founded from the three journals fulfilling the inclusion 
criteria; 67 of them (45.27 %) incorporated future related medical costs, 9 (6.08 %) 
included also future unrelated medical costs and none included future non-medical 
costs. Percentage of articles including future costs increased from 2008 (33 %) to 
2011(57 %) and no differences were detected between the three journals in the pro-
portion of economic evaluations incorporating future costs. ConClusions: Despite 
most of health economic guidelines advice the need of incorporating future costs in 
l economic evaluations, less than the half of articles reviewed incorporated them. 
Moreover, the inclusion of future unrelated medical costs and future non-medical 
costs was much lower. Results of economic evaluations can change dramatically 
depending on future costs inclusion. It is necessary to change the current practice 
and systematically include future related medical costs in the base case of economic 
evaluations and future unrelated medical costs and future non medical costs at 
least in sensitivity analysis.
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objeCtives: A range of linked electronic health records (LEHR) datasets are 
becoming available in the NHS in England. Understanding the benefits such large 
LEHR datasets can offer when performing cost-effectiveness analysis and over-
coming the challenges inherent in utilising such datasets using as a case study: 
the CALIBER (Cardiovascular Disease Research using Linked Bespoke Studies and 
Electronic Records) dataset to assess the cost-effectiveness of treatment of patients 
with chronic stable angina. Methods: The CALIBER dataset links primary care 
data from CPRD with secondary care data from HES, mortality data from ONS and 
disease-specific data from MINAP. This dataset is used to provide a generalisable 
baseline for cost-effectiveness models and to provide effectiveness estimates for 
treatments observed in the dataset. It is also used to explore decisions that, due 
to ethical concerns, could not be researched through RCTs - for example, optimal 
durations and combinations of treatments used in current practice. The statistical 
methods of matching, differences in differences and instrumental variables are 
used to overcome the selection bias problems associated with inferring treatment 
effects using observational data. The models are also combined with RCT results 
for novel treatments to assess their cost-effectiveness in a real world as opposed to 
trial setting. Results: There were significant challenges involved in working with 
LEHR ranging from correctly linking the data to plausibly imputing missing data 
and correcting for selection bias in estimates. Having addressed these challenges 
we were left with a rich dataset, from which to estimate costs, risks of health events 
and treatment effects in a generalisable real world setting. ConClusions: While 
the selection biases associated with the use of LEHR within the NHS makes them 
challenging to work with, the large sample sizes, generalisability of the results 
and relatively low cost of the research makes them a hugely valuable resource for 
economic evaluation.
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objeCtives: The retrieval of studies containing evidence of health state utility val-
ues (HSUVs) is currently problematic using generic bibliographic databases such as 
Medline. This is due to a lack of standardised search vocabulary and inadequate and 
inconsistent indexing. The objective of this project is to develop a bibliographic data-
base providing access to details of research studies containing health state utility val-
ues generated using the EQ-5D and other preference-based instruments. Methods: 
The initial phase of the project has focussed on the EQ-5D. An alpha version of the 
database was created using Mendeley reference management software. A corpus of 
potentially relevant studies was identified by searching Medline and by sifting the 
reference lists of systematic reviews of HSUVs in a range of diseases and conditions. 
The sifting of retrieved studies is an ongoing process. Studies are included in the 
database if they contain estimates of HSUVs. The names of instruments used in the 
